Long-term prognostic value of myeloperoxidase on acute coronary syndrome: a meta-analysis.
Recent studies have shown that myeloperoxidase (MPO) is involved in the pathogenesis of acute coronary syndrome (ACS). However, there were different results in different studies as to whether MPO could predict the long-term adverse outcomes in patients with ACS. In this paper we aimed to investigate the long-term prognostic value of MPO in ACS. We performed a meta-analysis to compare the long-term prognosis of ACS patients with high MPO and low MPO levels. The literature was retrieved by formal searches of electronic databases (PubMed, EMBASE, Medline, OVID, and web of knowledge) from inception to July 2010. A total of eight clinical trials were included in this meta-analysis involving 3902 patients. The high MPO level group showed a poorer outcome than the low MPO level group (14.3 vs. 10.4%, risk ratio [RR] 1.84, 95% confidence interval [CI] 1.42-2.37, p <0.00001). ACS patients with high MPO levels had a poor long-term prognosis.